Who
Mark Coleman
Director
Company insider
Files Form 4 as: Director, Axsome Therapeutics.
In numbers
- Trades disclosed
- 83
- Buys
- 8
- Sells
- 11
- Bought
- $867K
- Sold
- $20.5M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 19 Nov 2015
- Last trade
- 10 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $160K643 at $249.00 | filing |
| 10 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $160K643 at $249.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,429 | filing |
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,429 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,429 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,429 | filing |
| 5 Jun 2026filed 9 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,721 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,721 at $0.00 | filing |
| 2 Jun 2026filed 2 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.2M5,537 at $223.39 | filing |
| 2 Jun 2026filed 2 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.2M5,537 at $223.39 | filing |
| 1 Jun 2026filed 2 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M6,000 at $230.30 | filing |
| 1 Jun 2026filed 2 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M6,000 at $230.30 | filing |
| 29 May 2026filed 2 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M6,000 at $233.46 | filing |
| 29 May 2026filed 2 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M6,000 at $233.46 | filing |
| 26 Feb 2026filed 27 Feb 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $4.0M25,000 at $161.11 | filing |
| 26 Feb 2026filed 27 Feb 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $4.0M25,000 at $161.11 | filing |
| 23 Feb 2026filed 25 Feb 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $31K6,250 at $4.95 | filing |
| 23 Feb 2026filed 25 Feb 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,250 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,250 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $31K6,250 at $4.95 | filing |
News
No headline names them, or the companies they trade most, lately.